Results 1 to 10 of about 1,440 (183)

Venetoclax in the Therapeutic Strategy for BPDCN Management [PDF]

eJHaem
Background Venetoclax, a B‐cell lymphoma 2 (BCL‐2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials.
Margaux Poussard, Maxime Fredon, Imane Belakri, Sabeha Biichle, Florian Renosi, Evan Seffar, Morgane Boichut, Romain Boidot, Elodie Bôle‐Richard, Francis Bonnefoy, Marie Kroemer, Sophie Bonnot‐Perrin, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, Fanny Angelot‐Delettre   +15 more
doaj   +6 more sources

Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm [PDF]

Cancer Cell International
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy originating from precursors of plasmacytoid dendritic cells.
Meng Wang, Xiaotong Xue, Zhenzhen Wang, Chuan Wang, Gongqi Yu, Zihao Mi, Xu Sang, Jianwen Wang, Yongxia Liu, Xuechao Chen, Shengli Chen, Guizhi Zhou, Hong Liu, Hao Chen, Yonghu Sun, Furen Zhang   +15 more
doaj   +3 more sources

Case Report: Tumor-related hemorrhage determined treatment sequencing in blastic plasmacytoid dendritic cell neoplasm coexisting with gastric cardia adenocarcinoma [PDF]

Frontiers in Oncology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy that commonly presents with skin involvement and may also involve the bone marrow, peripheral blood, and lymph nodes.
Yuze Li, Chenggong Zhang, Xudong Song, Guoquan Tao   +3 more
doaj   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm secondary to acute myeloid leukemia with shared mutations in TET2 and DNMT3A: a case report and literature review [PDF]

Frontiers in Immunology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. Recent studies have highlighted its occurrence in patients with a history of preceding myeloid neoplasms.
Yao Sun, Yingjie Liu, Na Liu, Xiaohui Zhang, Wenrong Huang, Liangding Hu   +5 more
doaj   +2 more sources

Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysis [PDF]

Frontiers in Oncology
BackgroundTagraxofusp is a first-in-class CD123-targeted therapy approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Although venetoclax is not approved for BPDCN, limited use has been reported.
Anthony S. Stein, Guru Subramanian Guru Murthy, Pankit Vachhani, Sunil Iyer, Deborah Goldschmidt, Yipeng Gao, John Katsetos, Corey Pelletier, Tibor Kovacsovics   +8 more
doaj   +2 more sources

Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base [PDF]

Leukemia Research Reports
BPDCN is an aggressive myeloid malignancy characterized by unique expression of CD123, CD4, CD56, CD303, CD304, TCL1 and TCF4. The development of tagraxofusp, a CD123-directed cytotoxin, has revolutionized BPDCN treatment, especially for patients unfit ...
Nathan M. Krah, Rasmus Hoeg, Paul J. Shami, Shannon E. Elf, Lauren E. Lee, Naveen Pemmaraju, Ami B. Patel   +6 more
doaj   +2 more sources

A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm [PDF]

Journal of Hematology & Oncology
Background Patients with relapsed acute myeloid leukemia (AML), particularly following allogeneic stem cell transplant (alloHCT), have extremely limited therapeutic options.
Lihua E. Budde, Marissa M. Del Real, Joo Song, Tracey Stiller, Yan Wang, Ahmed Aribi, Karamjeet Sandhu, Ryotaro Nakamura, Emanuela C. Marcucci, Jian J. Wu, Kenneth Ng, Mary C. Clark, Brent Wood, Jamie R. Wagner, Jinny Paul, Christine E. Brown, Anthony Stein, Guido Marcucci, M. Suzette Blanchard, Joycelynne Palmer, Stephen J. Forman   +20 more
doaj   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program [PDF]

Discover Oncology
Background Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and aggressive hematologic malignancy originating from plasmacytoid dendritic cell precursors.
Astghik Voskanyan, Maria Badikyan, Marina Konopleva, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato M. Sergi, Ching-Tien Peng, Dickran Kazandjian, Justin Taylor, Funda Tekkesin, Hasanein Ghali, Karen Bedirian, Maria Paola Martelli, Enrico Attardi, Maria Teresa Voso, Mariam Abramashvili, Mazin Faisal Al-Jadiry, Michalis Michael, Min-Yu Su, Nare Martirosyan, Nerses Ghahramanyan, Nino Totogashvili, Pavel P. Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Shushan Hovsepyan, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Deniz Tuğcu, Ahmad Alhuraiji, Vassilios Lazaris, Gevorg Tamamyan, Naveen Pemmaraju   +38 more
doaj   +2 more sources

Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

Haematologica, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that presents with characteristic dark purple skin papules, plaques, and tumors, but may also involve the bone marrow, blood, lymph nodes, and central nervous system ...
Marlise R. Luskin, Andrew A. Lane
doaj   +1 more source

Regimen of Azacitidine Combined with GemOx in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report

Xiehe Yixue Zazhi, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly malignant hematological tumor derived from the precursor cells of plasmacytoid dendritic cells.
CHEN Xiaojun, LIU Yanquan, HU Xiaomei, HUANG Surong, SHEN Jianzhen   +4 more
doaj   +1 more source